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Abstract
An increasing number of applications require the expression of single-chain variable fragments
(scFv) fusion proteins in mammalian cells at the cell surface membrane. Here we assessed the
CD30-speciﬁc scFv HRS3, which is used in immunotherapy, for its ability to retarget lentiviral vectors
(LVs) to CD30 and tomediate selective gene transfer into CD30-positive cells. Fused to the C-terminus
of the type-II transmembrane protein hemagglutinin (H) of measles virus and expressed in LV pack-
aging cells, gene transfer mediated by the released LV particles was inefﬁcient. A series of point mu-
tations in the scFv framework regions addressing its biophysical properties, which substantially
improved production and increased the melting temperature without impairing its kinetic binding
behavior to CD30, also improved the performance of LV particles. Gene transfer into CD30-positive
cells increased ∼100-fold due to improved transport of the H-scFv protein to the plasma membrane.
Concomitantly, LV particle aggregation and syncytia formation in packaging cells were substantially
reduced. The data suggest that syncytia formation can be triggered by trans-cellular dimerization of
H-scFv proteins displayed on adjacent cells. Taken together, we show that the biophysical properties
of the targeting ligand have a decisive role for the gene transfer efﬁciency of receptor-targeted LVs.
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Introduction
Expression and stability of antibody single-chain variable fragments
(scFv) in any system, prokaryotic and eukaryotic alike, faces the prob-
lem of aggregation competingwith folding, and is thus strongly depend-
ent on the primary sequence of the antibody (Wörn and Plückthun,
2001). While eukaryotic cells are in general more forgiving in the ex-
pression yields of aggregation-prone antibody fragments than bacteria
(Schaefer and Plückthun, 2012), the stability against denaturation is a
molecular property and thus independent of the producing host. A poor
yield of in vivo folding (leading to aggregation and/or degradation in the
producing cell) can lead to limited secreted production (Jäger et al.,
2013) or expression at the cell surface when fused to transmembrane
proteins. The latter is relevant for cell surface display libraries (Doerner
et al., 2014), T cell receptors or chimeric antigen receptors (CARs)
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retargeted to tumor antigens (Lipowska-Bhalla et al., 2012; Rosenberg,
2012), and can be challenging for cell-type speciﬁc gene transfer with
viral vectors. The solutionmust therefore lie in improving the properties
of the antibody fragment by sequence engineering.
Viral vectors have become an important tool for the genetic modi-
ﬁcation of cells in basic research as well as molecular medicine. Lenti-
viral vectors (LVs) are unique in their ability to integrate the delivered
gene permanently into the host cell’s genome, thus producing a stable
genetic modiﬁcation not only in the initially transduced cell but also in
any off-spring cells resulting from cell division or differentiation
(Kaufmann et al., 2013). Usually LVs are pseudotyped with glycopro-
teins mediating transduction of a broad spectrum of cells, such as the
glycoprotein G of the vesicular stomatitis virus (VSV-G).
More and more applications, however, require selective transduc-
tion of a distinct cell-type present in a mixture of cells (ex vivo gene
transfer) or in a particular organ (in vivo gene transfer). Examples in-
clude, but are not limited to, the delivery of small interfering RNA or
transcription factors to modulate cell physiology, or suicide genes to
eliminate unwanted cells. Two systems of such cell entry targeted
LVs have been described, both relying on the destruction of the natural
receptor usage and on displaying a targeting domain on the vector par-
ticle surface, i.e. a high-afﬁnity ligand recognizing a cell surface mark-
er that deﬁnes the cell population of choice (Buchholz et al., 2009).
The system used here was initially established for oncolytic measles
viruses (Nakamura et al., 2005) and has then been extended to LVs
(Anliker et al., 2010). The scFv providing the receptor speciﬁcity is
fused to the C-terminus of measles virus hemagglutinin (H protein),
a type-II glycoprotein responsible for particle attachment to the cell
entry receptor. H protein forms dimers that are composed of an
N-terminal cytoplasmic tail, a large extracellular stem region and a
two-blade propeller-shaped head (Colf et al., 2007; Hashiguchi
et al., 2007). The exact position of the displayed scFv cannot be pre-
dicted, as structural information is not available for the ultimate
C-terminal residues of H. Moreover, H protein bears point mutations
to ablate its recognition sites for the natural measles virus receptors
and is truncated in its cytoplasmic tail to allow LV particle incorpor-
ation. Cytoplasmic tail truncation is also necessary for the fusion pro-
tein F, which forms a complex with H and mediates fusion of the
vector particle membrane with the host cell membrane upon receptor
contact by H.
Speciﬁcity for the target cell surface receptor of choice is deﬁned by
the targeting domain fused to H which can be, besides an scFv, a de-
signed ankyrin repeat protein (DARPin; Münch et al., 2011), or a nat-
ural protein ligand (IL13; Ou et al., 2012). This way, gene transfer
mediated by such LVs has been restricted to a variety of cell types
such as neurons, hematopoietic stem cells, tumor cells, subtypes of
endothelial cells and lymphocytes, with very high selectivity (Funke
et al., 2009; Anliker et al., 2010; Münch et al., 2011; Zhou et al.,
2012; Abel et al., 2013). The repertoire of cell types addressable by
this approach appears to be limited by the availability of suitable tar-
geting domains only. Among these, scFvs are preferred, since they are
most easily available (can be cloned from hybridomas or phage display
libraries), and in some cases special features of the parental antibody
such as activation of cells upon antigen contact can be transferred to
the vector particles (Zhou et al., 2012; Kneissl et al., 2013).
Antibody variable domains can be classiﬁed to particular sub-
groups according to their germline family, and these differ greatly in
functional expression and stability (Ewert et al., 2003b). The various
complementarity determining regions (CDRs) further contribute to
these properties—positively or negatively. Finally, afﬁnity maturation
during B cell development via somatic hypermutation will further
change the sequence and thus the stability properties as well. Typically,
mutations will be selected by the immune system for their contribution
to increasing afﬁnity (Klein et al., 2013), yet mutations may also inter-
fere with antibody stability and will be selected by the B cell as long as
they are above a certain threshold. The effects on stability appear to be
more pronounced in the scFv fragment than in the Fab fragment (or the
full antibody) because the constant domains CH1 and CL have a stabil-
izing function to the linked variable regions and partially compensate
for negative effects (Röthlisberger et al., 2005). However, fusion pro-
teins can only conveniently be made in the single-chain format.
Accordingly, yield, stability and resistance to aggregation of scFv
cloned from antibodies can be improved by mutating back to the
framework consensus (Forsberg et al., 1997; Wörn and Plückthun,
2001; Chowdhury and Vasmatzis, 2003; Honegger, 2008). Addition-
ally, there are distinct differences in the biophysical properties between
the germline frameworks regarding thermodynamic stability of
VH and VL chains individually and in various combinations (Ewert
et al., 2003b; Honegger et al., 2009). Consequently, changes of
some amino acids can be of beneﬁt to frameworks with poor stability
when adopted from frameworks with good biophysical properties
(Ewert et al., 2003a).
To be suitable as targeting domain on LVs, an scFv must fulﬁll
many requirements such as the efﬁcient transport to the cell surface
and folding in the context of a type-II transmembrane fusion protein,
high stability at 37°C, and high afﬁnity for the targeted cell surface
antigen. Therefore, the stability of an scFv used for receptor-targeted
LVs should also greatly impact on the gene transfer activity of the vec-
tor. We tested this hypothesis by engineering a new receptor-targeted
LV which delivers genes speciﬁcally into CD30-positive cells. The ori-
ginal CD30-speciﬁc scFv used was derived from the hybridoma line
HRS3 (Hombach et al., 1998), which had been employed as targeting
domain of cytokines (Heuser et al., 2004) and of a CAR for the ther-
apy of Hodgkin’s lymphoma (Hombach et al., 1998; Heuser et al.,
2004). Here, we show that an optimized framework of the HRS3-scFv
substantially enhances its cell surface transport, the yield of produced
CD30-speciﬁc LVs and ﬁnally the efﬁciency in gene delivery into
CD30-positive cells.
Material and methods
Plasmid construction
Starting from plasmid pHRS3-scFv (Hombach et al., 1998), the cod-
ing sequence of the HRS3-scFv was cloned via SﬁI/NotI restriction
into plasmid backbone pCG-HmutΔ18 (Anliker et al., 2010) providing
the coding sequence for truncated and mutated measles virus H pro-
tein and for an additional (G4S)3 linker (L3) between H and the scFv
resulting in plasmid pHL3-HRS3. HRS3 variants were obtained by
mutation with the QuikChange® Multi Site Directed Mutagenesis
Kit (Agilent Technologies). Primer details are available upon request.
To introduce a His tag at the C-terminal end of H in scFv-free LVs,
pHWTΔ18-His was cloned by replacing the PvuII-PstI fragment at
the 3′-end of the H-coding region in pHWTΔ18-Fab7 (Anliker et al.,
2010) by a de novo synthesized DNA fragment (GeneArt, Invitrogen)
containing the additional cloning sites SmaI, SﬁI and NotI between
H and the His tag coding sequence.
For plasmid pCR3.1-HRS3, the SﬁI site in the backbone of
pCR3.1-B1.8 (Sanz et al., 2002) was destroyed via T4 polymerase
ﬁll-in. A PCR product obtained with primers ClaI-SﬁI forward
(5′-ATG GCA TCG ATG GCG GCC CAG CCG GCC ATG GCC
CAG GTG CAA CTG CAG C-3′) and NotI reverse (5′-GGT GAT
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GAG AAC CTC TTG CGG CCG C-3′) on the template pHL3-HRS3
was inserted via ClaI/NotI. All further scFv coding sequences were
then exchanged via SﬁI/NotI.
The coding sequence of the extracellular domain of CD30 was
ampliﬁed by PCR with primers BssHII-CD30 forward (5′-CCT
AGT GGC GCG CAC TCC ATG GCC TTC CCA CAG GAT CGA
CCC-3′) and Not-CD30 reverse (5′-CAG ATA GCG GCC GCC
TGG GTC CCC AGG GGT GG-3′) from plasmid pcDNA3.1-V5-
His-Topo-CD30. The product was cut with BssHI and NotI and
cloned into the mammalian expression plasmid pCMV-hIgGI-Fc-XP
(kindly provided by Thomas Schirrmann, Braunschweig), providing
a C-terminal human IgG-Fc tag, to obtain phuFc-CD30.
The coding sequence for the anti-His scFv 3D5 (Lindner et al.,
1997) was PCR ampliﬁed using the primers 3D5SﬁI (5′-CCA GCA
GGC CCA GCC GGC CGA CAT TTT GAT GAC CCA AAC-3′)
and 3D5NotI (5′-CGG AGT CAG CGG CCG CCG CAG AGA
CAG TGA CGG TAG-3′). The PCR product was inserted via SﬁI/
NotI into the plasmid pDisplay-D9.29 (Rasbach et al., 2013) to gener-
ate pDisplay-3D5.
Cell lines and cultivation
HEK293T, HT1080 andHT1080 derived cells were cultivated in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS) and 2 mM L-glutamine. Raji and HuT78
cells were grown in RPMI 1640 medium supplemented with 10%
FBS and 2 mM L-glutamine.
HT1080-anti-His and HT1080-CD30 cells were established by
stable transfection of HT1080 cells with polyethylenimine using
pDisplay-3D5 and pcDNA3.1-V5-His-Topo-CD30, respectively, fol-
lowed by G418 (Invitrogen, Karlsruhe, Germany) selection and single
cell cloning for the HT1080-anti-His cells.
Vector particle production
Vector particles were generated as previously described (Rasbach
et al., 2013). In brief, HEK293T cells were transiently transfected
using polyethylenimine (PEI). Twenty-four hours prior to transfec-
tion, 2 × 107 cells were seeded into a T175 ﬂask. For standard produc-
tion of HRS3opt1#5-LV andHRS3opt2#2-LV, 5.25 μg of the plasmid
encoding FWTΔ30, 1.75 μg of the plasmid encoding an H variant,
14 μg of the packaging plasmid pCMVΔR8.9 (Zufferey et al., 1997)
and 14 μg of the transfer vector plasmid pSEW (Demaison et al.,
2002) encoding GFP were used. To obtain highest possible titers,
the H to F plasmid ratio was adapted for each H-HRS3 variant:
6 μg H and 2 μg F for HRS3-LV, and 4 μg H and 4 μg F for
HRS3opt1#3 and HRS3opt1#8-LV. MV-LV particles were produced
by co-transfection of cells with 4 μg pHWTΔ18-His, 6.7 μg pFWTΔ30,
9 μg pCMVΔR8.9 and 9 μg pSEW. Vector particles pseudotyped
with vesicular stomatitis virus G protein (VSVG) were produced by
co-transfecting cells with 6.13 μg pMD2.G (kindly provided by Didier
Trono, Lausanne, Switzerland), 11.38 μg pCMVΔR8.9 and 17.50 μg
pSEW. Components were mixed together with 2.3 ml of DMEMwith-
out additives. The transfection reagent mix was prepared by mixing
140 μl of 18 mM PEI with 2.2 ml of DMEM without additives. This
mixture was added quickly to the DNA mix, brieﬂy vortexed, and in-
cubated for 20 min at room temperature. The cell culture mediumwas
replaced by 10 ml of DMEM with 15% FBS and 2 mM L-glutamine,
and the transfection mix was added, resulting in 10% FBS total. After
24 h, themediumwas exchanged to DMEMwith 10%FBS and 2 mM
L-glutamine. Two days after transfection, the cell supernatant contain-
ing the pseudotyped vectors was ﬁltered (0.45 μm ﬁlter) and puriﬁed
by ultracentrifugation at 100 000×g and 4°Cover a 20% sucrose cush-
ion for 3 h. The pellet was re-suspended in 100 μl phosphate-buffered
saline (PBS).
The quantity of p24 gag in puriﬁed vector particle suspensions was
determined using the RETROtek HIV p24 antigen enzyme-linked im-
munosorbent assay (ELISA) kit (ZeptoMetrix Corporation, Buffalo,
NY) according to the manufacturer’s instructions. LV-particle num-
bers were calculated from p24 amounts assuming an average of
2000 molecules p24 per lentiviral particle (Wilk et al., 2001).
Production and puriﬁcation of scFv and CD30-Fc
Proteins were expressed in HEK293T cells and puriﬁed from the cell
culture medium. The day before transfection with PEI, 2 × 107
HEK293T cells were seeded in two 175 cm² ﬂasks. Seventy micro-
grams of pCR3.1-HRS3 or phuFc-CD30 were incubated with PEI as
described above and added to the cells. On the next day, medium was
removed, cells were washed once, before serum-free PANSERIN 293A
medium (Pan-Biotech) was added. Supernatants were harvested 48
and 72 h after transfection, cleared via ﬁltration (0.45 μm) and stored
at 4°C.
scFv was puriﬁed and concentrated by immobilized metal-ion
afﬁnity chromatography (IMAC) using HisTrap FF Crude columns
(1 ml, GE Healthcare, Freiburg, Germany) in an HPLC system
(Bioline, Knauer, Berlin, Germany), according to the manufacturer’s
instructions. CD30-Fc was puriﬁed via protein A afﬁnity chromatog-
raphy using a Sartobind® Protein A column (Sartorius, Göttingen,
Germany) in anHPLC system according to themanufacturer’s instruc-
tions. Protein concentration was calculated after measuring the
absorption at 280 nm in a micro-volume photometer (A280 measure-
ment, NanoDrop, Thermo Scientiﬁc).
SDS-PAGE, Coomassie staining and western blot
Western blot analysis of proteins and concentrated vector particles
was performed as described previously (Münch et al., 2011). In
brief, samples were either heated in denaturing buffer containing
10% β-mercaptoethanol or loaded to the gel without heating in non-
reducing Novex® Tris-Glycine SDS Sample Buffer (Invitrogen), sepa-
rated by gel electrophoresis, and either directly stained with Coomas-
sie Brilliant Blue or electrotransferred onto nitrocellulose membranes
(Amersham Biosciences, Freiburg, Germany).
The membranes were incubated with rabbit anti-F serum (F 431,
1:2000), rabbit anti-H serum (H 606, 1:1000) or mouse anti-p24
monoclonal antibody (clone 38/8.7.47, 1:1000; Gentaur, Aachen,
Germany) to detect F, H and p24 gag, respectively. scFv fragments
were detected with a monoclonal anti-myc antibody (ab18185,
Abcam, Cambridge, UK). Secondary antibodies conjugated with
horseradish peroxidase (1:2000; DakoCytomation, Hamburg,
Germany) were used. Signals were detected using the ECL plus west-
ern blotting detection system (GE Healthcare, Munich, Germany).
Speciﬁc deglycosylation of N-glycans of puriﬁed scFv was performed
using Protein Deglycosylation Mix (New England BioLabs) according
to the manufacturer’s protocol.
Surface plasmon resonance measurements
All experiments were performed at 25°C using PBST as running buffer
(10 mMPBS, pH 7.4 and 0.005% (v/v) Tween 20). A ProteOnXPR36
biosensor equipped with GLC and GLM sensor chips and coupling
reagents (10 mM sodium acetate, pH4.5, sulfo-N-hydroxysuccinimide,
1-ethyl-3-(3-dimethylaminpropyl)-carbodiimide hydrochloride [EDC]
and ethanolamine) was purchased from BioRad Inc. (Hercules, CA).
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For surface plasmon resonance (SPR) measurements, puriﬁed HRS3
variants and CD30-Fc were dialyzed (MWCO 3000; Spektrum
Labs) against PBS containing 0.001% Tween-20 at 4°C overnight.
Immobilizations were performed at 30 μl/min on a GLM chip.
Monoclonal mouse anti-penta-His antibody (Qiagen) was coupled
using a standard amine-coupling procedure: all six ligand channels
were activated for 5 min with a mixture of EDC (200 mM) and
sulfo-NHS (50 mM). Immediately after the surfaces were activated,
monoclonal mouse anti-penta-His antibody (15 μg/ml, 10 mM so-
dium acetate, pH 4.5) was injected across all six channels for 4 min.
Finally, channels were blocked with a 5 min injection of 1 M ethano-
lamine–HCl (pH 8.5). Final immobilization levels were ranging from
6000 to 6200 RU. The scFv variants were captured by simultaneous
injection along ﬁve of the separate whole ‘analyte’ channels (15 μg/ml,
30 μl/min) for 3 min and resulted in similar levels, ranging from 580 to
600 RU; buffer was injected along the sixth channel to provide an
‘in-line’ blank for double referencing purposes.
One-shot kinetic measurements were performed by injection of a di-
lution series of CD30-Fc (0, 12.5, 25, 50, 100 and 200 nM, 50 μl/min)
for 3 min along the ligand channels. Dissociation was monitored for
10 min. Kinetic datawere analyzed in ProteOnManager v. 2.1. Process-
ing of the reaction spot data involved applying an interspot-reference
and a double-reference step using an inline buffer blank (Myszka,
1999). The processed data from replicate one-shot injections were ﬁt
to a simple 1:1 Langmuir binding model without mass transport
(O’Shannessy et al., 1993).
Protein thermal shift assay
To determine the stability of the puriﬁed HRS3 variants, the Protein
Thermal Shift™ Assay (Life Technologies™) was used according to
the manufacturer’s protocol in an ABI PRISM® 7900HT real-time
PCR machine (Life Technologies™). Data were processed using
Prism 5 software (GraphPad Software) and the protein melting tem-
peratures were calculated as described previously (Niesen et al., 2007).
Transduction of cells, FACS analysis and competition
assay
To determine the titers of HRS3-LV and VSV-G-LV stocks,
HT1080-CD30 cells were transduced by at least four serial dilutions of
vector particles. GFP-positive cells were quantiﬁed after 2 days by ﬂow
cytometry. For this purpose, cells were washed twice using FACS wash
buffer (containing PBS w/o Mg2+ and Ca2+, 2% FBS and 0.5%
NaN3), ﬁxed using FACS ﬁx buffer (containing PBS w/o Mg
2+ and
Ca2+ with 1% formaldehyde) and stored at 4°C upon analysis. FACS
analysis was performed using the LSRII ﬂow cytometer (Becton Dickin-
son), and data were analyzed with FCS Express software (Denovo Soft-
ware). For titer calculation, dilutions were selected that showed a linear
correlation between dilution factor and number of GFP-positive cells. For
detection of CD30 at the surface, washed cells were incubated with
anti-CD30-PE antibody (Miltenyi Biotec, Bergisch Gladbach, Germany)
or isotype control antibody at 4°C for 1 h, washed twice and ﬁxed.
For the vector competition assay, different amounts of soluble
CD30-Fc were incubated with the LV variants for 15 min at 37°C
and then added to HT1080-CD30 cells. Two days after transduction,
the percentage of GFP-positive cells was determined by ﬂow cytometry
and the transduction efﬁciency was normalized to that obtained with-
out CD30-Fc treatment.
Immunoﬂuorescence microscopy
For immunoﬂuorescence of H protein variants, 4 × 104 HEK293T
cells were seeded into one well of an 8-well chambered coverglass
(LabTekII, Nunc, Wiesbaden, Germany). After 24 h, they were trans-
fected with 0.25 μg of an H plasmid variant using FuGENE® HD
Transfection Reagent (Promega) according to the manufacturer’s in-
structions. On the next day, cells were washed with PBS once and
ﬁxed in PBS supplemented with 4% formaldehyde for 20 min at
room temperature. Subsequently, cells were permeabilized with
0.5% Triton X-100 in PBS for 8 min at room temperature. After an
additional washing step and blocking in 5% chicken serum in PBS
for 45 min at room temperature, cells were incubated with anti-H
(clone K83, 1:20; Liebert et al., 1994) monoclonal antibody for 1 h
at 37°C. Secondary antibody conjugated with Cy3 dye (anti-mouse
IgG, 1:250; DAKO, Hamburg, Germany) was added and incubated
for 1 h at 37°C. Then, cells were washed twice with PBS and analyzed
using a laser scanning microscope (LSM510; Zeiss, Jena, Germany).
Micrographs are shown as false-color images generated with LSM
Image Browser (Zeiss, Jena, Germany).
Particle size measurement (nanoparticle tracking
analysis)
Particle size measurement of LVs was performed using the NanoSight
NS500 instrument (NANOSIGHT Ltd, Salisbury, UK). Vector stocks
were adjusted to 10 pg p24/ml with degased PBS. Each sample was
measured ﬁve times for 75 s at 24°C. NTA2.3 software (NANO-
SIGHT Ltd) was applied for particle identiﬁcation and size analysis.
Sequence alignments and computational modeling
The sequence of HRS3-scFv was aligned to germline sequences with
MS Excel with the macros and information provided at ‘AAAAA,
AHo’s Amazing Atlas of Antibody Anatomy’ at http://www.bioc.
uzh.ch/antibody (Honegger and Plückthun, 2001b).
Computational modeling for HRS3opt2#2 was based on the scFvs
PDB ID 2gki for VH and VL and PDB ID 1dl7 for the interface using
the CPHmodels 3.2 Server which is online available at http://www.cbs.
dtu.dk/services/CPHmodels/ (Nielsen et al., 2010). The structural
alignment, modiﬁcations to depict amino acids of HRS3 in the struc-
ture and visualization were performed with PyMOL (Schrödinger).
The resulting structure was further modiﬁed by GlyProt available on-
line at http://www.glycosciences.de/modeling/glyprot/ (Bohne-Lang
and von der Lieth, 2005).
Statistical analysis
Results are expressed as mean ± SD. Data were considered statistically
signiﬁcant for P < 0.05. Differences were evaluated by Student’s t-test.
All statistical calculations were done using Prism 5 software (Graph-
Pad Software).
Results
The HRS3-scFv was previously derived from the hybridoma line
HRS3 (Hombach et al., 1998) and has been used for anti-cancer thera-
peutic approaches (Heuser et al., 2004; www.clinicaltrials.gov:
NCT01192464 and NCT01316146). When applied as targeting do-
main on LVs as described for other scFvs (Anliker et al., 2010), we de-
tected selective gene transfer into a few CD30-positive cells by
microscopy at very low frequencies, which were at least two orders
of magnitude below that of other receptor-targeted LVs.
In order to improve the utility of the HRS3-scFv as targeting do-
main, we analyzed the sequence of the variable antibody regions
and identiﬁed the heavy chain to belong to subgroup 1 (muVH1)
and the kappa light chain to subgroup 6 (muVLκ6). When compared
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with the sequences of antibodies of matching murine germlines, as
published by IMGT®, the international ImMunoGeneTics informa-
tion system® (http://www.imgt.org) (Lefranc et al., 1999), we identi-
ﬁed several residues at highly conserved positions of the framework
regions that differed from the germline consensus sequence (Fig. 1A
and B). Additionally, both germlines carry residues which do not
occur in well behaving antibodies. We thus focused here on mutating
back germline liabilities in muVH1 to versions found in well behaved
subgroups and we mostly engineered the light chain back to its
muVLκ6 consensus.
Most of these non-germline residues may have been introduced by
somatic hypermutation during B cell development. Additionally, espe-
cially at the beginning of the variable regions, changes are most likely
introduced by mispairing of the primers used for PCR (E3/L4 VL
Fig. 1 Identiﬁcation and repair of crucial residues in the framework regions of the CD30-speciﬁc scFv HRS3. (A) One hundred and twenty sequences of mVH1 chains
(upper panel) and 12 sequences of mVLκ6 chains (lower panel) were aligned (uppermost sequence in each panel). Numbering of positions is according to Honegger
and Plückthun (2001b). All residues of the framework regions occurring at least once at a particular position are listed with decreasing frequency from top to bottom
with frequencies indicated by the color code. The sequences of the VH and VL chains of HRS3 and the HRS3 variants generated are depicted below. Amino acids
in the HRS3 sequence differing from germline consensus are labeled in red. Residues in the HRS3 variants are highlighted in black when changed to consensus and
in gray when changed to residues previously shown to enhance scFv stability. (B) Structure of HRS3 obtained by automated homology modeling. CDRs are labeled
in blue, residues identiﬁed in (A) are labeled in red and cysteine residues in yellow. The positions of the His tag (purple) and the N-glycan (green) were estimated and
modeled by PyMol. Enlargements depict in detail themissing cysteine bridge in VL, position of the glycosylation and amino acids within the interface. (C) Schematic
drawing of expression plasmids. Plasmid pHL3-HRS3 encodes the H-scFv fusion protein; pHWTΔ18-His the H protein derived from awild-typeMV strain (Funke et al.,
2009) and pCR3.1-HRS3 were used for the expression of scFv in HEK293T cells as secreted protein. Immunological tags for detection (His and myc), the signal
peptide (SP), the transmembrane domain (TMD) and cytoplasmic tail (CT) are indicated.
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instead of V3/M4VL), and further changes through PCRerrors cannot
be excluded.
The most dramatic alterations from the muVLκ6 subgroup consen-
sus in the light chain are a Cys→Tyr mutation at position 23, resulting
in a disruption of the completely conserved disulﬁde bond (C23–C106
in VL), aswell as amutation introducing a potential N-glycosylation site
(N20, V21, T22 in VL) in close vicinity of the disrupted disulﬁde bond.
Furthermore, the muVLκ6 subgroup germline is missing a common
threonine (T103 VL) present within the charge cluster of thewell behav-
ing subgroups (Ewert et al., 2003a,b) (Fig. 1B).
Within the heavy chain, liabilities are present at the muVH1 germ-
line level: a histidine (H50 VH) replaces a glutamine (Q50 VH) and a
charged aspartate (D51 VH), the highly ﬂexible non-polar glycine that
is preferred for β-strand formation at this position (G51 VH). Near the
CDR2, a highly conserved lysine (K73 VH) is substituted by aspara-
gine (N73 VH).
We hypothesized that these residues interfere with efﬁcient folding,
and thus with gene transfer by CD30-targeted LVs. Therefore, a series
of HRS3-scFv variants was generated by reverting residues to germline
consensus or to residues previously shown to enhance scFv production,
stability and folding (Forsberg et al., 1997; Honegger and Plückthun,
2001a; Ewert et al., 2003a; Honegger, 2008) (Fig. 1A). HRS3opt1#3
only reintroduces the single residue T103VL, HRS3opt1#8 also reintro-
duces the disulﬁde and removes the glycosylation site, HRS3opt1#5,
combines these and also adds two VH mutations potentially affecting
chain association, and ﬁnally HRS3opt2#2 adds additional mutations
previously deduced. These variants were cloned into plasmid backbone
pCR3.1 for secretion by transfected mammalian cells and into the
pCG-HmutΔ18-L3 plasmid backbone for expression as fusion protein
with the H protein (Fig. 1C).
The secreted scFv variants were produced in the same cell system,
i.e. HEK293T, as the targeted LVs. After transfection of the expression
plasmids, the scFvs were harvested from the cell culture supernatant
and puriﬁed by IMAC. Variant HRS3opt1#8, in which the disulﬁde
bond has been restored and the putative glycosylation site had been
mutated, was detected in cell lysate and cell culture supernatant by
western blot analysis; however, it could not be puriﬁed by IMAC
(data not shown), hinting at soluble aggregates. All other variants
were readily expressed and puriﬁed with yields above that of
HRS3-scFv. In fact, the yields increased with the number of ‘corrected’
residues from 79 μg for HRS3-scFv to 189 μg for HRS3opt2#2 per
175 cm² cell culture area (Table I). Gel electrophoretic analysis of
the puriﬁed proteins revealed lower electrophoretic mobility for
HRS3 and HRS3opt1#3 (Fig. 2A, lanes 1 and 2) when compared
with HRS3opt1#5 and HRS3opt2#2 (Fig. 2A, lanes 3 and 4). This
is in line with the presence of N-glycosylation in HRS3 and
HRS3opt1#3 which was conﬁrmed by enzymatic deglycosylation
(Fig. 2B). Gel electrophoresis under non-reducing conditions revealed
no insoluble aggregates and only small fractions of dimers for all var-
iants (Fig. 2A, lanes 6–9).
To determine the thermal stability of the scFv variants, we used the
ﬂuorescence-based thermal shift assay in which the heat-induced un-
folding process is monitored via a dye binding to hydrophobic residues
that are inaccessible in the folded protein (Niesen et al., 2007). The
stability of the scFv variants increased up to 74°C for HRS3opt1#5
(Table I). For the wild-type HRS3-scFv, we did not detect any shift
in ﬂuorescence intensity over a temperature range from 25 to 95°C,
indicating that this protein may be less stable already at room
temperature.
While the introduced changes in the framework regions increased
stability, they might also affect the binding afﬁnity. Therefore, we as-
sessed the CD30-binding properties of the scFv by SPRmeasurements.
The extracellular domain of CD30 was expressed as a secreted variant
in HEK293T cells, tagged with the dimerizing human Fc-domain
(CD30-Fc) to facilitate puriﬁcation and detection. The HRS3-scFv
variants were captured by an immobilized anti-His antibody via
their His tags with comparable efﬁciency (Supplementary Fig. S1A).
The kinetic proﬁle of the scFv/CD30 interaction was then determined
by measuring the association and dissociation rates of the dimeric
CD30-Fc. All scFv variants including the parental scFv showed similar
binding behavior (Supplementary Fig. S1B) with apparent dissociation
constants of 3.7–3.9 nM (Table II).
Having shown increased stability by the introduced mutations
while keeping the binding behavior unchanged, we next analyzed
the variants as fusion constructs with the measles virus H variant.
To become incorporated into LV vector particles, it is crucial that
the H-scFv proteins are efﬁciently expressed on the surface of the pro-
ducer cells. We therefore determined the cell surface expression of the
H-scFv proteins by ﬂow cytometry and the subcellular localization by
intracellular immunoﬂuorescence after transfection into HEK293T
cells. All variants were expressed at the cell surface without major
differences as revealed by ﬂow cytometry (data not shown), however
differences were detectable at the intracellular level. While the un-
modiﬁed HRS3-scFv and HRS3opt1#3 and HRS3opt1#8 mainly
held back the H protein in intracellular vesicles and the endoplasmic
reticulum (ER), H-HRS3opt1#5 and H-HRS3opt2#2 were predomin-
antly located at the extracellular membrane (Fig. 3A), reﬂecting the
best production and stability of these scFv when expressed as secreted
Table I. Main properties of the HRS3-scFv variants
Yield (μg/
175 cm²)
Melting
temperature (°C)
Glycosylated Particle number
per mla
Average particle size
(nm)
Syncytiab
formation
Functional titerc
(t.u./ml)
HRS3 78.7 <25d yes 7.6 × 1010 133.3 ± 18.6 +++ 3.1 × 104
HRS3opt1#3 126.1 66.4 yes 4.6 × 1011 121.3 ± 6.6 ++ 6.9 × 104
HRS3opt1#8 n.d.e n.d. no 2.8 × 1011 127.0 ± 7.4 +++ 1.4 × 104
HRS3opt1#5 179.2 74.5 no 9.9 × 1011 121.5 ± 5.9 + 1.5 × 106
HRS3opt2#2 188.8 71.9 no 1.0 × 1012 123.78 ± 4.3 + 2.3 × 106
aAverage values as determined by p24 ELISA, for standard deviations see Fig. 3.
b+++, strong syncytia formation; ++, moderate syncytia formation; +, residual/no syncytia formation as in MV-LV packaging cells.
cAverage values as determined on HT1080-CD30 cells, for standard deviations see Fig. 4.
dCould not be determined by thermal shift assay.
en.d., not determined.
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proteins. This suggests that the eukaryotic secretory quality con-
trol (Benyair et al., 2011) holds back variants HRS3-scFv and
HRS3opt1#3 and HRS3opt1#8.
Upon transfection into packaging cells the variants H-HRS3 and
H-HRS3opt1#8 reproducibly induced strong syncytia formation,
and H-HRS3opt1#3 to a lesser extent (Fig. 3B). Cells expressing
H-HRS3opt1#5 showed few and those expressing H-HRS3opt2#2
basically no syncytia. The viral vector particles were harvested from
the supernatant of the producer cells and puriﬁed by sedimentation
through a sucrose cushion. As a measure of viral vector particle con-
tent, the amount of the capsid protein p24 was determined. Highest
p24 values and thus similar particle numbers as in LV stocks pseudo-
typed with untargeted measles virus glycoproteins (MV-LV) were
present in stocks of HRS3opt1#5-LV and HRS3opt2#2-LV, inter-
mediate levels in HRS3opt1#3-LV and HRS3opt1#8-LV, and low
levels in HRS3-LV (Fig. 3C). Western blot analysis of the vector stocks
conﬁrmed that all vector types had incorporated the F and the H-scFv
protein (Fig. 3D).
Next, we determined the particle number in viral vector stocks using
the nanoparticle tracking analysis (NTA) technology (NanoSight
NS500), which calculates the hydrodynamic size of single particles
from their tracked diffusion velocity and therefore detects aggregated par-
ticles (Filipe et al., 2010).Wemeasured four independently produced vec-
tor stocks per variant. MV-LV particles included for comparison showed
a Gaussian distribution with an average hydrodynamic diameter of
139.3 ± 7.6 nm, and most particles exhibited a diameter of 123.8 ± 4.3
nm (Fig. 3E and F). Importantly, the particle number for MV-LV stocks
calculated via NTA did not differ from that determined by p24 ELISA
(Fig. 3H), thus nicely conﬁrming thatwe tracked p24-containing particles
byNTA. This holds true also for the scFv-displaying viral vector particles
with the exception of HRS3-LV and HRS3opt1#8-LV, for which
we determined ∼3- to 5-fold more particles by NTA than by p24
ELISA (Fig. 3H). The particle diameters differed signiﬁcantly bet-
ween the scFv-displaying vectors: whereas HRS3opt2#2-LV showed a
homogeneous size distribution with an average value of 144.25 ± 6.5 nm
resembling that of MV-LV particles, HRS3-LV showed an almost
biphasic size distribution with an average diameter of 174.5 ± 21.6 nm
(Fig. 3E and F). A particle diameter of 155 nm reﬂects the predicted
size of two linked spherical particles, each with a diameter of 120 nm.
Notably, in stocks of all variants the fraction of aggregated particles
and their average diameter decreased with the number of altered residues
(Fig. 3F and G).
The gfp gene transferred by the vectors allowed the calculation of
the titer of each stock as transducing units per ml (t.u./ml) by deter-
mining the amount of GFP-positive cells 48 h after transduction. As
target cells we used HT1080 cells engineered to express human
CD30 (HT1080-CD30) or a membrane-bound scFv recognizing the
His tag (HT1080-anti-His) at the C-terminus of the HRS3-scFv
(Fig. 4A). All LVs carrying an engineered scFv showed substantially
enhanced titers on both cell lines when compared with HRS3-LV.
The gene transfer efﬁciencymediated by the best variant,HRS3opt2#2-LV,
was ∼100-fold enhanced over HRS3 on HT1080-CD30 (Fig. 4B) and
∼25-fold enhanced on HT1080-anti-His cells (Fig. 4C).
Interestingly, with the exception of MV-LV, all vectors transduced
HT1080-anti-His cells considerably more efﬁciently than HT1080-
CD30 cells. The difference was especially pronounced for HRS3-LV,
HRS3opt1#3-LV and HRS3opt1#8-LV. Normalizing the transduc-
tion rates to p24 amounts (rel. transduction) revealed that on
HT1080-anti-His cells the differences in transduction rates were main-
ly reﬂected by the particle numbers present in the viral vector stocks.
On HT1080-CD30 cells, in contrast, the relative transduction
mediated by HRS3opt1#5-LV and HRS3opt2#2-LV was ∼10-fold
more efﬁcient than that of HRS3-LV (Fig. 4D and E). Thus, the mod-
iﬁcations introduced into the scFv framework regions did not only en-
hance particle release from packaging cells but also cell entry of vector
particles via CD30.
To prove cell-type speciﬁcity of the viral vector with the highest
titer (HRS3opt2#2-LV), cells with different levels of CD30 expression
were identiﬁed (Fig. 5A). HuT78 cells, naturally expressing CD30,
were used as target cells besides HT1080-CD30 for gene delivery.
As non-target cells, CD30-negative HT1080 and Raji cells were
incubated with HRS3opt2#2-LV. For comparison, vector particles
pseudotyped with the non-selective envelope glycoprotein VSV-G
were used. While VSVG-LV transduced both CD30-positive and
Fig. 2 Expression, puriﬁcation and deglycosylation of HRS3-scFv variants.
(A) The indicated scFv variants were expressed and secreted from HEK293T
cells and puriﬁed from the cell culture supernatant by His tag afﬁnity
chromatography. For each variant, 20 µl from the main elution fraction was
separated by SDS-polyacrylamide gel electrophoresis under reducing (lanes 1–4)
and under non-reducing (lanes 6–9) conditions, respectively. Proteins were
visualized by Coomassie Blue staining. (B) One microgram of puriﬁed scFv
was incubated in presence (+) or absence (−) of Protein Deglycosylation Mix.
Alterations in the molecular weight were analyzed by western blot analysis
using an myc-tag speciﬁc antibody.
Table II. Binding of dimeric CD30-Fc to HRS3-scFv variants
determined by SPR
ka [1/(M s)] kd (1/s) KD (M) Rmax
(RU)
χ2
(RU)
HRS3 1.16 × 105 4.30 × 10−4 3.71 × 10−9 128.26 20.18
HRS3opt1#3 1.22 × 105 4.52 × 10−4 3.71 × 10−9 171.88 20.76
HRS3opt1#5 9.75 × 104 3.81 × 10−4 3.91 × 10−9 198.11 34.56
HRS3opt2#2 1.08 × 105 4.06 × 10−4 3.75 × 10−9 197.34 23.72
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CD30-negative cells, only CD30-positive cells showed expression of
GFP after incubation with HRS3opt2#2-LV (Fig. 5B). Flow cytometry
data on GFP expression levels on all vector variants conﬁrm the sub-
stantial increase in vector transduction achieved by engineering of
HRS3 while retaining target receptor selectivity (Supplementary
Fig. S2). Overall, GFP expression levels in transduced HuT78 cells
were substantially lower than in HT1080-CD30 cells, which nicely
correlate with the CD30 expression levels in these cells (compare
Fig. 5A and B). Moreover, gene transfer into HT1080-CD30 cells
by HRS3opt2#2-LV was efﬁciently blocked with increasing amounts
of soluble CD30-Fc protein while VSVG-LV mediated transduction
remained unaffected (Fig. 5C). These data demonstrate that cell entry
of HRS3opt2#2-LV relies on the binding of vector particles to CD30.
Discussion
Here we investigated whether a CD30-speciﬁc scFv, which has shown
unsatisfactory performance in the retargeting of LVs, can be rescued
by introducing suitable framework mutations. Remarkably, the intro-
duced mutations converted the basically inactive parental HRS3-scFv
into an scFv that mediated efﬁcient and speciﬁc gene delivery
into CD30-positive cells, thus demonstrating that framework
Fig. 3 Characterization of vector packaging cells and LV particles. (A) Immunoﬂuorescence staining of the indicated H-HRS3 variants expressed in HEK293T cells
using an H-protein speciﬁc antibody. Samples were analyzed 1 day after transfection. Asterisks indicate the presence of H-HRS3 proteins in intracellular
compartments; arrowheads show localization at the plasma membrane (100-fold magniﬁcation). (B) Representative GFP ﬂuorescence microscopic pictures of
packaging cells producing the indicated LV types. Pictures were taken 48 h after transfection. Syncytia are labeled by dashed lines. (C) The amounts of p24
capsid protein in the indicated LV stocks as determined by quantitative ELISA. n = 5; mean values ± SD are shown; *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not
signiﬁcant by unpaired t-test. (D) Incorporation of H-scFv and F proteins in the indicated LV stocks as determined by western blot using the H-speciﬁc antibody
H606 (top panel), the F-speciﬁc antibody F431 (center panel) and a p24-speciﬁc antibody (bottom panel). (E–G) NTA analysis of particle size. (E) Size distribution
(diameter) of representative stocks of HRS3-LV, HRS3opt2#2-LV and MV-LV. The vertical line indicates the threshold for aggregated particles, assuming that
aggregation results in a diameter increase of at least 25% when two spherical particles each of a diameter of 120 nm aggregate. (F) Mean particle diameter of
four independent stocks per variant and (G) percentage of aggregated particles. (H) Comparison of particle quantiﬁcation via p24-ELISA (white bars) and NTA
(black bars). The amounts of p24 were converted to particle numbers assuming 2000 p24 molecules per particle (Wilk et al., 2001). Statistics for (E–H): n = 4;
mean ± SD is shown; *P < 0.05; **P < 0.01; ***P < 0.001; n.s., not signiﬁcant by unpaired t-test.
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modiﬁcations can improve scFvs applied for receptor-targeted LVs. To
get a comprehensive picture about the impact of the introduced muta-
tions on the molecular level, we characterized both the LV particles
displaying the scFv variants and the scFvs themselves as secreted
proteins released from transfected HEK293T cells. The introduced
changes, designed to improve the biophysical properties of the scFv
not only increased thermostability and expression of the scFv in
HEK293T cells but also reduced aggregation of vector particles and
Fig. 4 Gene transfer titers of vector stocks. (A) Schematic drawing of scFv-displaying LV, the H-scFv/F glycoprotein complex and target cells. The H-scFv protein is
depicted as dimer with a stalk domain inserted in the plasmamembrane and globular heads displaying the scFv and carrying point mutations that inactivate natural
receptor binding (‘blinding’ symbolized by dotted trapezium). The trimeric F protein is shown as monomer in complex with H-scFv. Vector particles enter
HT1080-CD30 cells via CD30, HT1080-anti-His via the cell-surface-displayed His-tag-speciﬁc scFv 3D5. While stable scFv mediate LV entry into both cell types,
LVs displaying unfolded scFv only enter HT1080-anti-His cells. (B–E) Titers of scFv displaying LVs were determined on HT1080-CD30 (B and D) or
HT1080-anti-His (C and E) cells by quantifying GFP gene transfer in a dilution series of vector stocks. Titers of MV-LV stocks were determined on Raji cells
(B and D) besides HT1080-anti-His cells. Relative titers (D and E) were determined by normalizing the amounts of transducing units (t.u./ml) to the p24 amounts.
n = 5; mean ± SD is shown; *P < 0.05; **P < 0.01; n.s., not signiﬁcant by unpaired t-test.
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syncytia formation in the packaging cells. Our work therefore directly
shows that the biophysical properties of the targeting molecule have
implications for the generation of targeted LVs.
We investigated a series of HRS3-scFv variants containing an in-
creasing number of modiﬁed residues in the framework regions of
the VL and VH chains. The reasons for this strategy are 2-fold: First,
the CDRs which determine binding afﬁnity and speciﬁcity remain un-
touched. Secondly, these strategies are generic and not limited to a
given antibody.
Thermostability of the soluble scFv beneﬁtted most from the intro-
duced mutation E103T VL. There is a strong preference for amino
acids with β-branched side chains (Thr, Val, Ile) at this position favor-
ing β-strand conformation (Zhu and Blundell, 1996) while the gluta-
mate side chain likely extends to the interface of VH/VL in close
proximity to Q46 VL-Q46 VH which are stabilizing the interface
(Fig. 1B). Improvements on the vector particle level, in contrast, be-
came most obvious when residues HD50/51QG in VH were repaired
(Table I). Interestingly, D51 is localized in the periphery to the VH/VL
interface close to Q46 VL-Q46 VH as well, but in contrast to E103, it
belongs to the VH chain (Fig. 1B), suggesting that this exchange further
improved the inter-domain stability.
The two most prominent deviations from consensus in HRS3 are
located in the VL chain: the (unintended) glycosylation at residue N20,
which is present as demonstrated by our data, and the Tyr substitution
of C23 that forms a disulﬁde bridge with C106, which is totally con-
served across all antibodies and is a major determinant of stability. For
the corresponding disulﬁde bridge in VH, it was previously demon-
strated that the presence of a tyrosine instead of cysteine at position
106 results in overpacking of the core and thus strong destabilization
of the scFv (Proba et al., 1997). Most likely, Y23 twists outward to
relieve overpacking and the glycosylation of N20 in VL helps to
limit the perturbation of the β strand to the C-terminal end of the
strand. Yet, HRS3-opt1#8 in which we reconstituted the cysteine
bridge (Y23C) and removed the glycosylation site in VL (N20V/
T21I) showed, if at all, only minor improvements compared with
HRS3, despite the E103T mutation that beneﬁtted HRS3-opt1#3.
The absence of the glycosylation site was, however, tolerated once
the VH/VL interface was further stabilized in HRS3opt1#5, which is
consistent with previously published ﬁndings that the domains can sta-
bilize each other (Wörn and Plückthun, 1998; Jäger and Plückthun,
1999a). Thus, VL appears to have been the limiting factor for the sta-
bility of the whole scFv. It is therefore likely, that the accidental pres-
ence of an N-glycosylation could overcome the other defects of the
overall unstable VL, thus enabling the successful use of HRS3 as tar-
geting domain in CARs (Hombach et al., 1998). Glycosylation intro-
duces a protein to the ER quality control (Benyair et al., 2011), which
is normally secured by the presence of N-glycosylation in the CH2 do-
main of IgG. Since this antibody was cloned from a hybridoma, the
original IgG must have had both deviations, and thus the B cell prob-
ably already selected N-glycosylation as a compensation for the other
framework defects. That glycosylation can facilitate folding and
increase solubility is well documented for other proteins and also
scFvs (Lizak et al., 2011).
A remarkable result of this work is the strongly reduced or even
lost formation of syncytia in the vector packaging cells with variants
HRS3opt1#5 and HRS3opt2#2. The reduction of syncytia formation
correlated with strongly increased viral vector particle release and im-
proved gene transfer rates. How can a few changes in the framework
regions of an scFv make such a difference for syncytia formation? In
principle, syncytia form, once the F protein has been activated by the
H protein after receptor contact, irrespectively if H protein itself or the
targeting domain (here the scFv) have attached to the target cell by
binding the targeted cell surface receptor (Nakamura et al., 2005).
Interestingly, membrane fusion can also be activated if the targeting
domain is not directly linked to H protein but presented as a separate
third component within the vector envelope (Rasbach et al., 2013).
HEK293T packaging cells, however, are CD30 negative. The syncytia
formed by packaging cells producing, e.g.HRS3-LVorHRS3opt1#8-LV,
Fig. 5 Speciﬁcity of the CD30-targeted LV. (A) CD30 surface expression levels in Raji, HT1080, HuT78 and HT1080-CD30 cells were determined by ﬂow cytometry
using the CD30-speciﬁc antibody anti-CD30-PE (Miltenyi Biotec, black lines). As controls, cells were analyzed unstained (ﬁlled gray areas) or incubated with an
isotype control antibody (dashed lines). The mean ﬂuorescence intensities (MFIs) are provided for each cell type and histogram. (B) CD30-positive
(HT1080-CD30, HuT78) and CD30-negative (HT1080, Raji) cells were incubated with VSVG-LV or HRS3opt2#2-LV each applied at a dose of 1 t.u. per cell (MOI 1).
Transduced cells were analyzed by ﬂuorescence microscopy for GFP expression 48 h later. (C) Increasing amounts of soluble CD30-Fc protein were used to
compete with transduction mediated by HRS3opt2#2 and VSVG-LV on HT1080-CD30 cells (MOI 1). The percentage of transduced cells is shown relative to that
observed without CD30-Fc. n = 3; mean ± SD is shown; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n.s., not signiﬁcant by unpaired t-test.
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therefore, cannot be due to CD30 binding. Thus, another trigger has to
be considered. It is well established that reduced interface stability be-
tween VH and VL leads to the dimerization of scFv, especially, if their
local concentration is high (Wörn and Plückthun, 2001). Each viral
vector-producing cell expresses a high density of H-scFv proteins at its
surface and is in tight contact with neighboring cells. Therefore, the
scFv displayed on Hmay form a dimer with an scFv from a neighboring
cell, thus providing the required receptor contact for H protein to activate
F and trigger cell-to-cell fusion (Fig. 6). Alternatively, neighboring cells
may have been connected to each other via hydrophobic residues exposed
after unfolding of one domain, which is especially likely after opening
of the interface. Previous studies demonstrated that for cell-to-cell fusion
to proceed, a density of 104 receptor molecules per cell can be sufﬁcient
(Hasegawa et al., 2007; Münch et al., 2011). Moreover, the afﬁnity of
H protein for the MV receptor CD46 is rather low with 1 × 10−7 M
when compared with that of other viruses such as HIV (10−8 M for
CD4) (Santiago et al., 2002; Wang, 2002) and lies within the range of
the association constants between the VL and VH chains (Horne et al.,
1982; Jäger and Plückthun, 1999b). It is thus conceivable that trans-
dimerization of scFvs displayed on adjacent cell membranes can indeed
trigger cell-to-cell fusion and may therefore be preferred over cis-
dimerization between scFv present on the same cell.
This hypothesis also explains the reduced syncytia formation ob-
served for variants HRS3opt1#5 and HRS3opt2#2. These scFvs
gave higher yields in mammalian cells, had a substantially increased
thermal stability, and when displayed on vector particles, mediated
gene transfer via the targeted receptor CD30 as efﬁciently as via a
membrane-bound His-tag-speciﬁc scFv. It is reasonable that the His
tag fused to the scFv C-terminus can attach LV particles to cells dis-
playing a His-tag-speciﬁc scFv even if the scFv displayed on H is mis-
folded or unstable. Interestingly, the enhanced VH/VL interface
stability seems to have inﬂuenced the cellular localization of the
H-scFv protein as well: H-HRS3opt1#5 and H-HRS3opt2#2 showed
a dramatic change in cellular localization toward the cell membrane
while the strong intracellular staining observed for H-HRS3 indicates
that this protein accumulated in the Golgi, ER or aggresomes (Kopito
and Sitia, 2000), fully consistent with the action of the secretory qual-
ity control of eukaryotic cells (Benyair et al., 2011).
Another line of evidence for the formation of scFv dimers across
cells, i.e. between H-HRS3 proteins present on opposing membranes,
was revealed by laser-based NTA based on Brownian motion. Only
very few reports used this approach before for the quantiﬁcation of
lentiviral particles (Gutiérrez-Granados et al., 2013; Papanikolaou
et al., 2013). Our data are well in line with the study by Gutiérrez-
Granados et al. (2013) with respect to particle size and the compliance
of particle numbers determined byNTA and p24-speciﬁc ELISA. NTA
can thus be considered as additional or alternative method for the
quality control of LV stocks. Interestingly, the diameter and the p24
content-normalized number of particles were signiﬁcantly increased
in batches of HRS3- and HRS-3opt1#8-LV, both vector particles dis-
playing rather instable scFv. Possible explanations include, but are not
limited to, enforced aggregation of particles due to scFv instability and
release of apoptotic vesicles (Théry et al., 2009), especially from syn-
cytia. Notably, aggregation was greatly reduced already by the single
framework mutation in HRS3opt1#3 as for all other HRS3 variants.
Thus, particle aggregation seems to be less sensitive toward scFv in-
stability than cell-to-cell fusion.
Taken together, our data support the importance of the biophysic-
al properties of the protein exposed on the surface of LVs, in this case,
the thermal and interface stability of scFv used for the retargeting. Low
vector titers and strong syncytia formation in packaging cells can be
overcome by stability engineering of the antibody framework regions.
Sequence alignments of the VL and VH chains to germline consensus
can be a straightforward approach to identify and repair destabilizing
residues (Wörn and Plückthun, 2001; Ewert et al., 2003a). Likewise,
this approach can improve the yield of scFv upon expression in all
cells, including mammalian cells. Besides, it will be informative to
assess if the scFv identiﬁed here as optimal for the display on LVs
will also be beneﬁcial as targeting domains for CARs, for which
an inﬂuence of the displayed scFv on their surface expression has
Fig. 6 Working model to explain syncytia induction in packaging cells
expressing instable scFv. The H-HRS3 protein is depicted as dimer with a
stalk domain inserted in the plasma membranes of neighboring cells and
with globular heads displaying the scFv and carrying point mutations that
inactivate natural receptor binding (‘blinding’ symbolized by dotted
trapezium). The trimeric F protein is shown as monomer in complex with
H-HRS3. (A) Membrane fusion and thus syncytia formation is triggered by
dimerization of instable scFv displayed on neighboring packaging cells or by
exposed hydrophobic residues (indicated by coiled lines) contacting
unidentiﬁed parts of the neighboring cell. (B) When a stabilized HRS3 variant
is displayed, syncytia formation is abolished and vector particle release
enhanced.
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previously also been demonstrated (Alonso-Camino et al., 2013;
Lipowska-Bhalla et al., 2013). Independently from this, the scFv
HRS3opt2#2 described here may serve as targeting domain not only
for LVs but also for oncolytic measles viruses and possibly be applied
for novel therapeutic strategies to target CD30-positive tumors such as
Hodgkin lymphoma.
In more general terms, the LVs are surprisingly sensitive against the
aggregation tendency of the displayed targeting protein. Therefore, the
use of stability-engineered antibody fragments or the use of scaffold
proteins, where the whole library has been engineered for good bio-
physical properties, such as DARPins (Boersma and Plückthun,
2011; Münch et al., 2011), may be an important component in the
further development of viral receptor targeting.
Supplementary data
Supplementary data are available at PEDS online.
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